Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Welcome
- Conflict of interests and disclaimer
- Part 1: introduction and history
- What is pharmacovigilance?
- A proactive science
- Why do we need pharmacovigilance?
- Reasons for knowledge deficits: clinical trials
- Reasons for knowledge deficits: the pre-licensing period
- New challenges
- History and disasters
- History and disasters: 20th and 21st century
- Some examples out of 40 years
- Science and knowledge
- Areas of research (1)
- Areas of research (2)
- Pharmacovigilance and public health
- Ecologic traces in waters: examples
- Pharmacovigilance and public health: data collection
- Clinical medicine and expertise: knowledge
- Clinical medicine and expertise: expertise
- A pharmacovigilantee and his watchdog
- More in part 2 of the talk
- Thank you
Topics Covered
- Pharmacovigilance
- Pharmacotherapy
- Reasons for knowledge deficits in clinical trials
- Pharmacovigilance and public health
- Clinical medicine and expertise
Links
Categories:
External Links
Talk Citation
Hagemann, U. (2023, June 29). The multidimensional landscape of pharmacovigilance: introduction and history [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/UOGQ4376.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Ulrich Hagemann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
The multidimensional landscape of pharmacovigilance: introduction and history
Published on June 29, 2023
33 min
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Ladies and gentlemen, my
name is Ulrich Hagemann.
Welcome to this talk about
the multidimensional landscape
of pharmacovigilance.
0:13
I got my university
education in Pharmacy
and Biochemistry at the
Free University of Berlin.
Thereafter I started to work for
the German medicines
National Drug Agency,
the Federal Institute
of drugs and
medical devices, first in
Berlin and later in Bonn.
Since 1996, I was leading
the pharmacovigilance
department at
this institute until
my retirement in 2011.
Currently, I'm retired and
a member of the Editorial Board,
of the International Journal of
Risk and Safety in Medicine.
0:55
These are my conflicts
of interests.
I have no conflicts of
interests to be declared.
The views expressed in this
presentation reflect my
personal views of the issue.
1:09
I have decided to
divide my talk into
two parts because there are
different issues which
relate to pharmacovigilance,
but which are not really
straightforward connected.
In this first part,
I would like to talk about
the history and disasters
in pharmacovigilance,
I would like to address
the science and
knowledge which are
needed in pharmacovigilance
and the areas of research.
I would like to outline what is
the link between
pharmacovigilance and
public health and what is
the needed clinical
medicine expertise
in pharmacovigilance.
Hide